Clinical trial
Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr…
NCT00002956 · University of Alabama at Birmingham, Other · Withdrawn
Key facts
| NCT number | NCT00002956 |
|---|---|
| Title | Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants |
| Official title | A Phase I Pilot Trial to Evaluate the Toxicity of Allogeneic Epstein-Barr Virus Specific T-Lymphocytes for the Treatment of EBV-Associated Lymphoproliferative Diseases in Organ Transplant Recipients |
| Lead sponsor | University of Alabama at Birmingham, Other |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Biological |
| Interventions | allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes |
| Enrollment | 0 |
| Start date | Nov 1, 1996 |
| Primary completion | Feb 1, 2002 |
| Completion | Feb 1, 2002 |
| First posted | Jul 19, 2004 |
| Last update posted | Mar 21, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: